MRUS Merus NV
Price (delayed)
$43.01
Market cap
$2.97B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.35
Enterprise value
$2.69B
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed
Highlights
MRUS's debt is down by 19% year-on-year and by 10% since the previous quarter
Merus's equity has soared by 82% YoY but it has decreased by 8% from the previous quarter
Merus's net income has decreased by 39% YoY but it has increased by 12% from the previous quarter
Merus's gross profit has decreased by 18% YoY
The revenue has declined by 18% year-on-year
Key stats
What are the main financial stats of MRUS
Market
Valuations
Earnings
Shares outstanding
69.09M
Market cap
$2.97B
Enterprise value
$2.69B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.54
Price to sales (P/S)
76.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
74.4
Revenue
$36.13M
Gross profit
$36.13M
Operating income
-$272.07M
Net income
-$215.33M
EBIT
-$237.96M
EBITDA
-$235.49M
Free cash flow
-$187.5M
Per share
Balance sheet
Liquidity
EPS
-$3.35
EPS diluted
-$3.35
Free cash flow per share
-$2.92
Book value per share
$9.46
Revenue per share
$0.56
TBVPS
$12.16
Total assets
$782.69M
Total liabilities
$134.77M
Debt
$9.91M
Equity
$647.93M
Working capital
$482M
Debt to equity
0.02
Current ratio
6.54
Quick ratio
6.18
Net debt/EBITDA
1.2
Margins
Efficiency
Dividend
EBITDA margin
-651.7%
Gross margin
100%
Net margin
-595.9%
Operating margin
-753%
Return on assets
-28.5%
Return on equity
-35.2%
Return on invested capital
-79.7%
Return on capital employed
-34.2%
Return on sales
-658.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRUS stock price
How has the Merus stock price performed over time
Intraday
8.61%
1 week
-3.24%
1 month
-8.66%
1 year
-4.85%
YTD
2.28%
QTD
2.19%
Financial performance
How have Merus's revenue and profit performed over time
Revenue
$36.13M
Gross profit
$36.13M
Operating income
-$272.07M
Net income
-$215.33M
Gross margin
100%
Net margin
-595.9%
The operating margin has plunged by 111% YoY and by 17% from the previous quarter
MRUS's operating income has shrunk by 74% YoY and by 18% QoQ
MRUS's net margin has dropped by 69% year-on-year but it is up by 12% since the previous quarter
Merus's net income has decreased by 39% YoY but it has increased by 12% from the previous quarter
Growth
What is Merus's growth rate over time
Valuation
What is Merus stock price valuation
P/E
N/A
P/B
4.54
P/S
76.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
74.4
The EPS has grown by 15% from the previous quarter but it has contracted by 12% YoY
Merus's equity has soared by 82% YoY but it has decreased by 8% from the previous quarter
The P/B is 23% less than the last 4 quarters average of 5.4
The P/S is 101% higher than the 5-year quarterly average of 35.0 but 18% lower than the last 4 quarters average of 85.5
The revenue has declined by 18% year-on-year
Efficiency
How efficient is Merus business performance
The ROS has plunged by 74% YoY but it has grown by 6% from the previous quarter
The ROE has grown by 30% YoY and by 22% from the previous quarter
The ROA is up by 24% year-on-year and by 22% since the previous quarter
The ROIC has grown by 23% from the previous quarter and by 8% YoY
Dividends
What is MRUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRUS.
Financial health
How did Merus financials performed over time
Merus's total assets has soared by 72% YoY but it has decreased by 7% from the previous quarter
The total liabilities has grown by 36% YoY but it has contracted by 4.7% from the previous quarter
MRUS's debt is 98% smaller than its equity
Merus's equity has soared by 82% YoY but it has decreased by 8% from the previous quarter
MRUS's debt to equity is down by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.